JL
Therapeutic Areas
ALX Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Evorpacept (ALX148) + Trastuzumab + Chemotherapy (ASPEN-Breast) | ENHERTU®-experienced HER2-Positive Breast Cancer | Phase 2 |
| Evorpacept + SARCLISA® + Dexamethasone | Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 |
| Evorpacept + Trastuzumab + CYRAMZA® + Paclitaxel (ASPEN-06) | 2L or 3L Advanced HER2-Overexpressing Gastric/GEJ Adenocarcinoma | Phase 2 |
| Evorpacept + Zanidatamab | HER2-Expressing Breast Cancer and Other Cancers | Phase 2 |
| Evorpacept + Trastuzumab + Chemotherapy (ASPEN-09) | Advanced / Metastatic HER2+ Breast Cancer | Phase 1 |
| ALX2004 | EGFR-Expressing Solid Tumors (NSCLC, CRC, HNSCC, ESCC) | Phase 1 |
| Evorpacept + Fam-Trastuzumab Deruxtecan-Nxki (ENHERTU) | HER2-positive Breast Cancer, Metastatic Breast Cancer (I-SPY Trial) | Phase 1/1b |